Eloralintide (LY-3841136) sodium (ready in 6 weeks) peptide

Eloralintide (LY-3841136) sodium (ready in 6 weeks) peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

{γGlu}-CNTATCATG-{Orn}-LAE-{(α-Me-Phe)}-LVRSSN-{(N-Me-Asn)}-FGP-{Lys(γGlu-γGlu-C20 diacid)}-LPPTEVGSNTY-NH2 (Methylene bridge: Cys2-Cys7)

{γGlu}-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gly-{Orn}-Leu-Ala-Glu-{(α-Me-Phe)}-Leu-Val-Arg-Ser-Ser-Asn-{(N-Me-Asn)}-Phe-Gly-Pro-{Lys(γGlu-γGlu-C20 diacid)}-Leu-Pro-Pro-Thr-Glu-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Methylene bridge: Cys2-Cys7)

39

99.08%

C₂₀₁H₃₁₉N₄₉O₆₅S₂

4526.1

Synthetic

Powder

Eloralintide is a novel, once-weekly subcutaneous amylin receptor agonist developed by Eli Lilly for weight management. It selectively activates the amylin 1 receptor (AMY1R) with 12-fold selectivity over the calcitonin receptor in recombinant human receptor assays, distinguishing it from non-selective agonists such as cagrilintide. In recent studies, eloralintide dose-dependently reduced food intake and body weight in diet-induced obese rats, primarily through fat mass loss, while eliciting significantly less conditioned taste avoidance than cagrilintide.

In a Phase 1 single-ascending-dose study (N=48, mean BMI 27.5 kg/m²), single doses of 4 mg and 12 mg produced mean body weight reductions of −2.5% and −4.4% at week 4, respectively. Gastrointestinal tolerability was favorable, with only 2 of 36 eloralintide-dosed subjects reporting GI-related events.

In a Phase 2 study (N=263, mean BMI 39.1 kg/m²), 48-week administration achieved dose-dependent body weight reduction: −9% (1 mg), −12% (3 mg), −18% (6 mg), −20% (9 mg), −20% (6–9 mg), and −16% (3–9 mg), versus −0.4% for placebo. The most frequently observed events were nausea and fatigue. These findings support eloralintide as a promising candidate for weight management.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Briere DA, Qu H, Lansu K, He MM, Moyers JS, Coskun T, Long A, Allen D, O'Farrell L, Bowen B, Pratt E, Tidemann-Miller B, Tham LS, Ibriga H, Alsina-Fernandez J, Mather KJ, Haupt A, Bhattachar SN. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025 Dec;102:102271. doi: 10.1016/j.molmet.2025.102271. Epub 2025 Oct 16. PMID: 41109426; PMCID: PMC12640043.
• Billings LK, Hsia S, Bays H, Tidemann-Miller B, O'Hagan J, Tham LS, Butler A, Kazda C, Mather KJ, Coskun T. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025 Dec 6;406(10520):2631-2643. doi: 10.1016/S0140-6736(25)02155-5. Epub 2025 Nov 6. PMID: 41207310.

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.